Companies: 10,795·Total market cap: $144.5T
Replimune Group, Inc.

Replimune Group, Inc.

REPLNASDAQHealthcare● Active
$8.91
$-0.56(-5.91%)
Market Cap$735722035
P/E Ratio—
52W High$13.24
52W Low$1.5
Overview

Replimune Group, Inc.（REPL）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

repl · 股价预测 · 15 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 15 位华尔街分析师

SellBuy

Buy

15 位分析师

共识

评级分布

Strong Buy
0
Buy
7
Hold
6
Sell
2
Strong Sell
0
合计: 15 · 买入占比: 46.7%

12 个月目标价

High

$14.00

Consensus

$14.00

+56.4% upside

Low

$14.00

Median: $14 · Last Close: $8.95

Replimune Group, Inc.（REPL）的分析师共识为 Buy，基于过去 3 个月内 15 位华尔街分析师的评级。REPL 的 12 个月平均目标价为 $14.00，相对当前价 $8.95 代表 +56.4% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

📅
财报窗口期

在 ±3 天财报窗口期内暂停短期预测，以避免不可靠信号。

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Elevated Volatility — Earnings Window Active (±3 days)· Technical signals still shown. M3 predictions paused.

Market Sentiment

NEUTRAL

Based on 14 technical indicators

0%86%14%
0Buy
12Neutral
2Sell
RSI (14)50.0Neutral
MACDNEUTRAL

Refreshes daily from EOD close

Moving Averages · REPL · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$9.43SELL
MA 10$0.00NEUTRAL
MA 20$0.00NEUTRAL
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $REPL · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$9.21SELL
EMA 10$0.00NEUTRAL
EMA 20$0.00NEUTRAL
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $REPL · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Wedbush2026-06-01
Maintains
Neutral→Neutral
Wedbush2026-04-13
Downgrade ↓
Outperform→Neutral
Jefferies2026-04-13
Downgrade ↓
Buy→Hold
JP Morgan2026-04-13
Downgrade ↓
Neutral→Underweight
Cantor Fitzgerald2026-04-13
Downgrade ↓
Overweight→Neutral
HC Wainwright & Co.2026-04-13
Downgrade ↓
Buy→Sell
Leerink Partners2026-04-13
Downgrade ↓
Outperform→Market Perform
Piper Sandler2026-02-05
Maintains
Overweight→Overweight
Wedbush2026-02-04
Maintains
Outperform→Outperform
BMO Capital2025-11-03
Upgrade ↑
Underperform→Market Perform

Wall Street analysts have recently issued updated ratings on Replimune Group, Inc. (REPL) stock. Of the recent 92 rating actions, 8 were upgrades and 15 were downgrades. 15 analysts currently cover REPL.

分析师推荐趋势

Buy ratings0 → 0
Hold ratings1 → 1
Sell ratings1 → 0↓ 1

REPL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$2M

↓ 92.8% YoY

Revenue Next Year

$18M

↑ 963.4% YoY

EPS This Year

$-3.25

EPS Next Year

$-1.81

↓ 44.4% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast REPL EPS of $-3.25 for the current fiscal year, based on estimates from 5 analysts. The REPL revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

REPL 股价预测由两类独立数据源支撑：来自 15 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。REPL 的共识目标价为 $14.00（+56.4% 上行空间），分析师共识为 Buy。

Replimune Group, Inc. 在 NASDAQ 上市，代码 REPL。REPL 在 2027 年的整体展望偏积极，在覆盖分析师中约 47% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

REPL 预测 · 8 个问题

根据 15 位华尔街分析师，REPL 的 12 个月平均目标价为 $14.00，最高 $14.00、最低 $14.00。若有图表，中位目标价可在上方查看。相对当前价 $8.95，隐含约 +56.4% 的上行空间。

REPL 目标价REPL 分析师目标价REPL 12个月目标价目标价 REPL

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.